The effect of spironolactone in patients with obesity at risk for heart failure: proteomic insights from the HOMAGE trial

[1]  S. Heymans,et al.  Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. , 2020, JACC. Heart failure.

[2]  S. Heymans,et al.  The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial , 2020, European heart journal.

[3]  M. Bessler,et al.  Interacting hepatic PAI-1/tPA gene regulatory pathways influence impaired fibrinolysis severity in obesity , 2020, The Journal of clinical investigation.

[4]  S. Heymans,et al.  Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial , 2020, European journal of heart failure.

[5]  C. Buechler,et al.  Chemerin Isoforms and Activity in Obesity , 2019, International journal of molecular sciences.

[6]  M. Furuhashi.  Fatty Acid-Binding Protein 4 in Cardiovascular and Metabolic Diseases , 2019, Journal of atherosclerosis and thrombosis.

[7]  G. Hotamisligil,et al.  Adipokine FABP4 integrates energy stores and counterregulatory metabolic responses , 2019, Journal of Lipid Research.

[8]  A. Mebazaa,et al.  Adrenomedullin in heart failure: pathophysiology and therapeutic application , 2018, European journal of heart failure.

[9]  Thomas A. Slater,et al.  The insulin like growth factor and binding protein family: Novel therapeutic targets in obesity & diabetes , 2018, Molecular metabolism.

[10]  G. Helfer,et al.  Chemerin: a multifaceted adipokine involved in metabolic disorders , 2018, The Journal of endocrinology.

[11]  M. Packer.  Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity , 2018, Circulation.

[12]  G. Vilahur,et al.  New insights into the role of adipose tissue in thrombosis , 2017, Cardiovascular research.

[13]  Akshay S. Desai,et al.  Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. , 2017, JACC. Heart failure.

[14]  J. McMurray,et al.  Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS‐HF trial , 2017, European journal of heart failure.

[15]  P. Ponikowski,et al.  Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure , 2017, Circulation. Heart failure.

[16]  F. Zannad,et al.  Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats , 2016, British journal of pharmacology.

[17]  I. Janszky,et al.  Body Mass Index, Abdominal Fatness, and Heart Failure Incidence and MortalityCLINICAL PERSPECTIVE , 2016 .

[18]  Z. Tahergorabi,et al.  Leptin and its cardiovascular effects: Focus on angiogenesis , 2015, Advanced biomedical research.

[19]  J. Després,et al.  Ectopic visceral fat: A clinical and molecular perspective on the cardiometabolic risk , 2014, Reviews in Endocrine and Metabolic Disorders.

[20]  R. Harris.  Direct and indirect effects of leptin on adipocyte metabolism. , 2014, Biochimica et biophysica acta.

[21]  Michael D. Jensen,et al.  Reprint: 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. , 2013, Journal of the American Pharmacists Association : JAPhA.

[22]  C. Rotimi,et al.  The roles of IL-6, IL-10, and IL-1RA in obesity and insulin resistance in African-Americans. , 2011, The Journal of clinical endocrinology and metabolism.

[23]  G. Fonarow,et al.  Epidemiology and risk profile of heart failure , 2011, Nature Reviews Cardiology.

[24]  M. Nowicki,et al.  Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. , 2009, Clinical nephrology.

[25]  S. Kihara,et al.  Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. , 2009, Cardiovascular research.

[26]  W. Sessa,et al.  Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. , 2008, The American journal of pathology.

[27]  Y. Iwakura,et al.  Increased fat:carbohydrate oxidation ratio in Il1ra−/− mice on a high-fat diet is associated with increased sympathetic tone , 2008, Diabetologia.

[28]  Kazuhiro Takahashi,et al.  Adrenomedullin is a novel adipokine: Adrenomedullin in adipocytes and adipose tissues , 2007, Peptides.

[29]  D. Ribatti,et al.  The role of adrenomedullin in angiogenesis , 2005, Peptides.

[30]  J. Ordóñez‐Llanos,et al.  Human Apolipoprotein A-II Enrichment Displaces Paraoxonase From HDL and Impairs Its Antioxidant Properties: A New Mechanism Linking HDL Protein Composition and Antiatherogenic Potential , 2004, Circulation research.

[31]  K. Kangawa,et al.  Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. , 1993, Biochemical and biophysical research communications.